Clinical Trials · NCT03311724
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 111
- Start date
- Oct 2017
- Locations
- 13 sites, United States
- Primary endpoint
- Change From Baseline in Haemoglobin A1c (HbA1c)